Category Archives: Patent

“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council

Source: Health Policy Watch 9th July, 2019   Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged … Continue reading

Posted in Delinkage, Patent, R&D, Uncategorized | Leave a comment

The Cost of Cancer: WHO Report Says Expensive Drugs ‘Impairing’ Access to Cure

Source: NEWS18 1st Feb 2019, New Delhi A recent report by the World Health Organisation (WHO) says the standard treatment for breast cancer can drain 10 years of average annual income in India. Forty-five-year old Virendra Sharma’s father was diagnosed … Continue reading

Posted in Access to Medecines, Cancer, Drug prices, India, Patent | Leave a comment

Time to put a stop to the abuse of orphan drug regulation- the latest scandal

10th Jan 2019, New Delhi Source: Medicines Law and Policy Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch Erasmus medical centre in Rotterdam. For … Continue reading

Posted in Access to Medecines, Cancer, Innovation, orphan drug, Patent, Price hikes, Pricing | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Document exclusivity weakens Norwegian pandemic preparedness

Source: Dagens Medisin | June 20, 2018 IMAGINE THAT A large global o, break of contagious disease also includes Norway, such as a new flu-like disease with high risk of transmission and mortality. Imagine that there is only one effective drug, … Continue reading

Posted in Compulsory Licensing, Patent, Patents | Leave a comment